CL2020003255A1 - Proteínas de fusión que comprenden progranulina - Google Patents

Proteínas de fusión que comprenden progranulina

Info

Publication number
CL2020003255A1
CL2020003255A1 CL2020003255A CL2020003255A CL2020003255A1 CL 2020003255 A1 CL2020003255 A1 CL 2020003255A1 CL 2020003255 A CL2020003255 A CL 2020003255A CL 2020003255 A CL2020003255 A CL 2020003255A CL 2020003255 A1 CL2020003255 A1 CL 2020003255A1
Authority
CL
Chile
Prior art keywords
progranulin
fusion proteins
proteins
ftd
polypeptide
Prior art date
Application number
CL2020003255A
Other languages
English (en)
Inventor
Paolo Gilbert Di
Todd P Logan
Kathryn M Monroe
Ankita Srivastava
Lengerich Bettina Van
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of CL2020003255A1 publication Critical patent/CL2020003255A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan en la presente proteínas de fusión que comprenden progranulina y un polipéptido Fc. También se proporcionan en la presente métodos para el uso de dichas proteínas para el tratamiento de trastornos asociados con la progranulina (por ejemplo, una enfermedad neurodegenerativa, tal como demencia frontotemporal (FTD)).
CL2020003255A 2018-06-18 2020-12-16 Proteínas de fusión que comprenden progranulina CL2020003255A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862686579P 2018-06-18 2018-06-18
US201862746338P 2018-10-16 2018-10-16

Publications (1)

Publication Number Publication Date
CL2020003255A1 true CL2020003255A1 (es) 2021-05-28

Family

ID=67138158

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020003255A CL2020003255A1 (es) 2018-06-18 2020-12-16 Proteínas de fusión que comprenden progranulina

Country Status (17)

Country Link
US (3) US20210284702A1 (es)
EP (1) EP3807322A1 (es)
JP (1) JP7517997B2 (es)
KR (1) KR20210027377A (es)
CN (1) CN112424233A (es)
AU (1) AU2019288212A1 (es)
BR (1) BR112020025306A2 (es)
CA (1) CA3101202A1 (es)
CL (1) CL2020003255A1 (es)
EC (1) ECSP20081591A (es)
IL (1) IL279510B2 (es)
MX (1) MX2020012518A (es)
PE (1) PE20210323A1 (es)
PH (1) PH12020552189A1 (es)
SG (1) SG11202011743SA (es)
TW (1) TWI874321B (es)
WO (1) WO2019246071A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE057432T2 (hu) 2015-04-07 2022-05-28 Alector Llc Anti-sortilin antitestek és ezek alkalmazási módjai
RU2725737C2 (ru) * 2015-05-29 2020-07-03 Регенерон Фармасьютикалс, Инк. Животные, отличные от человека, с нарушением в локусе c9orf72
ES2932759T3 (es) 2017-02-17 2023-01-25 Denali Therapeutics Inc Polipéptidos de unión al receptor de transferrina diseñados
MA50746A (fr) 2017-10-02 2020-08-12 Denali Therapeutics Inc Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive
RS64034B1 (sr) 2018-07-13 2023-04-28 Alector Llc Anti-sortilin antitela i načini njihove upotrebe
CN112839955A (zh) * 2018-08-16 2021-05-25 戴纳立制药公司 经工程改造双特异性蛋白
CN113164627B (zh) * 2018-10-16 2024-10-29 戴纳立制药公司 治疗和监测颗粒体蛋白前体相关病症的方法
CN113614110B (zh) 2019-02-20 2025-03-25 戴纳立制药公司 抗trem2抗体及其使用方法
AU2020411480B2 (en) * 2019-12-23 2023-12-21 Denali Therapeutics Inc. Progranulin variants
AU2021208482B2 (en) 2020-01-13 2025-12-11 Denali Therapeutics Inc. Anti-TREM2 antibodies and methods of use thereof
WO2021241616A1 (ja) 2020-05-27 2021-12-02 アステラス製薬株式会社 抗ヒトｎｒ１抗体誘導体
US20210393787A1 (en) * 2020-06-17 2021-12-23 Bioasis Technologies, Inc. Compositions and methods for treating frontotemporal dementia
JP7817757B2 (ja) * 2020-09-18 2026-02-19 アイユーシーエフ－エイチワイユー（インダストリー－ユニバーシティ コーオペレーション ファウンデーション ハンヤン ユニバーシティ） ＰＴＰｓｉｇｍａ－Ｆｃ融合タンパク質およびそれを含む薬学組成物
KR102666958B1 (ko) * 2020-09-18 2024-05-23 한양대학교 산학협력단 PTPsigma-Fc 융합단백질 및 이를 포함하는 약학 조성물
CR20230178A (es) 2020-10-14 2023-07-26 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas
CN116420078A (zh) 2020-10-14 2023-07-11 戴纳立制药公司 用于治疗和监测额颞痴呆的方法
TW202340459A (zh) * 2021-12-17 2023-10-16 美商戴納立製藥公司 包含α—Ｌ—艾杜糖醛酸酶之融合蛋白及其方法
JP2025514645A (ja) * 2022-04-12 2025-05-09 エフ． ホフマン－ラ ロシュ アーゲー 中枢神経系に対して標的化された融合タンパク質
EP4526344A1 (en) * 2022-05-16 2025-03-26 Denali Therapeutics Inc. Transferrin receptor-binding domains and proteins comprising the same
CN120529913A (zh) * 2022-12-06 2025-08-22 普罗泰克有限公司 靶向性分拣蛋白
WO2024263567A2 (en) 2023-06-21 2024-12-26 Eli Lilly And Company Compounds for the delivery of granulin across the blood brain barrier
WO2025051953A1 (en) * 2023-09-07 2025-03-13 Novo Nordisk A/S Sortilin-1 binders, constructs and uses thereof
WO2025137213A1 (en) 2023-12-20 2025-06-26 Denali Therapeutics Inc. Fusion proteins comprising acid alpha-glucosidase enzymes and methods thereof
WO2025166077A1 (en) * 2024-01-31 2025-08-07 Alector Llc Compositions comprising progranulin and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120039865A1 (en) * 2008-08-19 2012-02-16 Yale University Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin
HUE057432T2 (hu) * 2015-04-07 2022-05-28 Alector Llc Anti-sortilin antitestek és ezek alkalmazási módjai
PE20221007A1 (es) * 2015-06-24 2022-06-15 Hoffmann La Roche Anticuerpos anti-receptor de transferrina con afinidad disenada
CN107698684B (zh) * 2016-08-03 2021-09-28 广东东阳光药业有限公司 包含突变的免疫球蛋白Fc部分的GLP-1融合蛋白
EP3583118B1 (en) 2017-02-17 2025-06-11 Denali Therapeutics Inc. Transferrin receptor transgenic models
US10143187B2 (en) 2017-02-17 2018-12-04 Denali Therapeutics Inc. Transferrin receptor transgenic models

Also Published As

Publication number Publication date
SG11202011743SA (en) 2021-01-28
ECSP20081591A (es) 2021-01-29
BR112020025306A2 (pt) 2021-03-09
JP2021527656A (ja) 2021-10-14
IL279510B2 (en) 2025-11-01
WO2019246071A1 (en) 2019-12-26
JP7517997B2 (ja) 2024-07-17
PH12020552189A1 (en) 2021-06-28
US20230406898A1 (en) 2023-12-21
IL279510B1 (en) 2025-07-01
CA3101202A1 (en) 2019-12-26
KR20210027377A (ko) 2021-03-10
CN112424233A (zh) 2021-02-26
MX2020012518A (es) 2021-02-16
EP3807322A1 (en) 2021-04-21
US20210284702A1 (en) 2021-09-16
IL279510A (en) 2021-01-31
AU2019288212A1 (en) 2020-12-03
TWI874321B (zh) 2025-03-01
US20260001925A1 (en) 2026-01-01
TW202016152A (zh) 2020-05-01
PE20210323A1 (es) 2021-02-18

Similar Documents

Publication Publication Date Title
CL2020003255A1 (es) Proteínas de fusión que comprenden progranulina
PE20230036A1 (es) Variantes de progranulina
CL2022000036A1 (es) Polipéptidos modificados y usos de los mismos (divisional de solicitud no. 201900261)
CY1124309T1 (el) Τροποποιημενα πολυπεπτιδια fgf-21 και χρησεις εξ αυτων
CL2019002922A1 (es) Anticuerpos anti-péptido beta amiloide n3pglu y sus usos.
MX378790B (es) Moleculas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunes.
MX2020006322A (es) Proteinas de fusion il-2 fc modificadas.
CL2022001712A1 (es) Variantes de progranulina
CO2018002450A2 (es) Proteínas de fusión de gitrl y usos de las mismas
MX2020006635A (es) Proteína de fusión enzimática terapéutica que tiene una nueva estructura y uso de la misma.
CR20190480A (es) Uso de antagonistas de klk5 para el tratamiento de una enfermedad
CY1122644T1 (el) Πρωτεϊνες συντηξης tatk-cdkl5, συνθεσεις, φαρμακοτεχνικες μορφες και η χρηση αυτων
MX2021007235A (es) Tubulisinas y conjugados de proteina-tubulisina.
BR112021014944A2 (pt) Toxinas apxia, apxiia e apxiiia inativas
CL2019002155A1 (es) Proteínas de fusión del factor ix y procedimientos de preparación y utilización de las mismas.
ECSP22019177A (es) Proteínas de fusión nkg2d y sus usos
CL2020002507A1 (es) Variantes de lfa3 y composiciones y usos de las mismas
AR115565A1 (es) Proteínas de fusión que comprenden progranulina
EA202190062A1 (ru) Слитые белки, содержащие програнулин
AR119984A1 (es) Proteínas de fusión nkg2d y sus usos
TH180250A (th) อุปกรณ์สำหรับการนำส่งสิ่งปลูกฝังเทียมและวิธีการใช้พวกมัน
UA97336U (en) Glasses-transformers